Last reviewed · How we verify
APG-2575(Lisaftoclax )
APG-2575 (Lisaftoclax) is a BCL-2 family protein inhibitor that promotes apoptosis by blocking anti-apoptotic proteins in cancer cells.
APG-2575 (Lisaftoclax) is a BCL-2 family protein inhibitor that promotes apoptosis by blocking anti-apoptotic proteins in cancer cells. Used for Relapsed or refractory acute myeloid leukemia (AML), Relapsed or refractory B-cell lymphomas.
At a glance
| Generic name | APG-2575(Lisaftoclax ) |
|---|---|
| Sponsor | Ascentage Pharma Group Inc. |
| Drug class | BCL-2/BCL-xL inhibitor |
| Target | BCL-2, BCL-xL |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Lisaftoclax selectively inhibits BCL-2 and BCL-xL proteins, which are overexpressed in many hematologic and solid malignancies and prevent programmed cell death. By blocking these anti-apoptotic factors, the drug restores the intrinsic apoptotic pathway, allowing cancer cells to undergo programmed death. This mechanism is particularly relevant in cancers with high BCL-2 dependence.
Approved indications
- Relapsed or refractory acute myeloid leukemia (AML)
- Relapsed or refractory B-cell lymphomas
Common side effects
- Tumor lysis syndrome
- Cytopenias (neutropenia, thrombocytopenia, anemia)
- Nausea and vomiting
- Diarrhea
- Fatigue
Key clinical trials
- Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL (PHASE2)
- Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma (PHASE2)
- A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus. (PHASE1, PHASE2)
- Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease (PHASE2)
- A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia (PHASE3)
- Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4). (PHASE3)
- A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL (PHASE2)
- Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- APG-2575(Lisaftoclax ) CI brief — competitive landscape report
- APG-2575(Lisaftoclax ) updates RSS · CI watch RSS
- Ascentage Pharma Group Inc. portfolio CI